BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12062396)

  • 1. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug.
    Smee DF; Bailey KW; Sidwell RW
    Antiviral Res; 2002 May; 54(2):113-20. PubMed ID: 12062396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir.
    Smee DF; Bailey KW; Wong M; Sidwell RW
    Antiviral Res; 2000 Sep; 47(3):171-7. PubMed ID: 10974369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir.
    Smee DF; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2000 Jul; 11(4):303-9. PubMed ID: 10950392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
    Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
    Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
    Quenelle DC; Collins DJ; Kern ER
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir.
    Bray M; Martinez M; Kefauver D; West M; Roy C
    Antiviral Res; 2002 Jun; 54(3):129-42. PubMed ID: 12062386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
    Smee DF; Bailey KW; Sidwell RW
    Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
    Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
    Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
    Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
    Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.
    Smee DF; Wandersee MK; Bailey KW; Wong MH; Chu CK; Gadthula S; Sidwell RW
    Antiviral Res; 2007 Jan; 73(1):69-77. PubMed ID: 16712967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
    Smee DF; Bailey KW; Wong MH; Sidwell RW
    Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.
    Smee DF; Sidwell RW
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(1-2):375-83. PubMed ID: 15043161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
    Quenelle DC; Collins DJ; Kern ER
    Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
    Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of cidofovir treatment of cowpox virus infection.
    Goff A; Twenhafel N; Garrison A; Mucker E; Lawler J; Paragas J
    Virus Res; 2007 Sep; 128(1-2):88-98. PubMed ID: 17524511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge.
    Bray M; Martinez M; Smee DF; Kefauver D; Thompson E; Huggins JW
    J Infect Dis; 2000 Jan; 181(1):10-9. PubMed ID: 10608745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.
    Kern ER; Hartline C; Harden E; Keith K; Rodriguez N; Beadle JR; Hostetler KY
    Antimicrob Agents Chemother; 2002 Apr; 46(4):991-5. PubMed ID: 11897580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
    Smee DF; Bailey KW; Sidwell RW
    Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
    Smee DF; Sidwell RW
    Antiviral Res; 2003 Jan; 57(1-2):41-52. PubMed ID: 12615302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
    Keith KA; Hitchcock MJ; Lee WA; HolĂ˝ A; Kern ER
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.